Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study

Wei Wang, Yueying Mao, Jing Ruan, Huacong Cai, Jin Ye, JunLi Chen, Liang Wang, Wenrong Huang, Yan Zhang, Jian Li

Blood (2025) 146 (Supplement 1): 5383.

https://doi.org/10.1182/blood-2025-5383

Published: 2025

Journal Articles

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Blood (2025) 146 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2025-1796

Published: 2025

Journal Articles

A prospective, multicenter, real-world study of glofitamab in Chinese patients with relapsed or refractory large B-cell lymphoma

Li Wang, Jiayin He, Zhihua Yao, Hongmei Jing, Songfu Jiang, Xia Zhao, Wenrong Huang, Hongbin Lu, Zhao Peiqi, Lihong Liu, Jianzhen Shen, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7252.

https://doi.org/10.1182/blood-2025-7252

Published: 2025

Journal Articles

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma

Yuqin Song, Qingqing Cai, Ye Guo, Haisheng Liu, Mingxia Wang, Wenrong Huang, Mingzhi Zhang, Yanyan Liu, Lanfang Li, Yuerong Shuang, Zengjun Li, Cuizhen Niu, Lin-Chi Chen, Jingxia Chen, Yan Xie

Blood (2025) 146 (Supplement 1): 3740.

https://doi.org/10.1182/blood-2025-3740

Published: 2025

Journal Articles

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Blood (2025) 146 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2025-5830

Published: 2025

Journal Articles

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Blood (2025) 146 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2025-5818

Published: 2025

Journal Articles

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory follicular lymphoma

Yuqin Song, Ye Guo, Qingqing Cai, Haisheng Liu, Mingxia Wang, Wenrong Huang, Mingzhi Zhang, Lanfang Li, Yanyan Liu, Yuerong Shuang, Zengjun Li, Cuizhen Niu, Andrew Chow, Jingxia Chen, Yan Xie

Blood (2025) 146 (Supplement 1): 5372.

https://doi.org/10.1182/blood-2025-5372

Published: 2025

Journal Articles

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment

Menghan Liu, Wen Gao, Wenrong Huang, Xinan Cen, Yuan Jian, Huixing Zhou, jing jia, Wenming Chen, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 5766.

https://doi.org/10.1182/blood-2025-5766

Published: 2025

Journal Articles

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Blood (2025) 146 (Supplement 1): 3689.

https://doi.org/10.1182/blood-2025-3689

Published: 2025

Journal Articles

Is autologous hematopoietic stem cell transplantation as consolidation therapy superior to chemotherapy alone in newly diagnosed intermediate-high risk DLBCL patients?

Shuozi Liu, Lan Ma, Hui Liu, Jiefei Bai, Wenrong Huang, JunLi Chen, Li Bao, Shan Gao, Wanling Sun, Zhenling Li, Min Wang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 1888.

https://doi.org/10.1182/blood-2025-1888

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Blood (2024) 144 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2024-204513

Published: 2024

Journal Articles

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Lin Gui, Keshu Zhou, Ting Liu, Yan Qin, Hongmei Jing, Wenyu Li, Yajun Li, Wenrong Huang, Zhen Wang, Xiuhua Sun, Quan Li, Faming Zhang, Henry Li, Lei Zhang, Peng Sun, Xinbao Gao, Yuankai Shi

Blood (2024) 144 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2024-194771

Published: 2024

Journal Articles

Efficacy of Zanubrutinib Combined with Immunochemotherapy in Newly Diagnosed MYD88-Mutated Diffuse Large B-Cell Lymphoma: A Retrospective Single-Center Study

Wenrong Huang, Xiubin Xiao, Xilin Chen, Shunzong Yuan, Yi Ma, Shihua Zhao, Yun Lu, Junli Chen, Nana Cheng, Hua Yin, Feng Pan, Yueqi Wang

Blood (2024) 144 (Supplement 1): 6528.

https://doi.org/10.1182/blood-2024-201880

Published: 2024

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Blood (2024) 144 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2024-201978

Published: 2024

Journal Articles

Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R 2) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study

Wei Wang, Xu Zhang, Qihui Li, Hua Yin, Xiubin Xiao, Jian Li, Wenrong Huang, Hongmei Jing, Yan Zhang

Blood (2024) 144 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2024-198294

Published: 2024

Journal Articles

Daratumumab Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Yi Ma, Xiubin Xiao, Shunzong Yuan, Xilin Chen, Shihua Zhao, Nana Cheng, Yun Lu, Junli Chen, Yueqi Wang, Wenrong Huang

Blood (2023) 142 (Supplement 1): 6687.

https://doi.org/10.1182/blood-2023-184811

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: Psychological Burden and Influencing Factors from Mycosis Fungoides and Sézary Syndrome Patients in China

Tun-Ying Hsu, Huiping Sun, Zhiming Li, Wenrong Huang, Linna Xie, Xiaojing Yan, Haifeng Zhao, Ki Hyon Kim, Yuankai Shi

Blood (2023) 142 (Supplement 1): 7354.

https://doi.org/10.1182/blood-2023-179638

Published: 2023

Journal Articles

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Blood (2023) 142 (Supplement 1): 4458.

https://doi.org/10.1182/blood-2023-181385

Published: 2023

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2023) 142 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2023-180736

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

A prospective, multicenter, real-world study of glofitamab in Chinese patients with relapsed or refractory large B-cell lymphoma

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory follicular lymphoma

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Is autologous hematopoietic stem cell transplantation as consolidation therapy superior to chemotherapy alone in newly diagnosed intermediate-high risk DLBCL patients?

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Efficacy of Zanubrutinib Combined with Immunochemotherapy in Newly Diagnosed MYD88-Mutated Diffuse Large B-Cell Lymphoma: A Retrospective Single-Center Study

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R 2) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study

Daratumumab Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: Psychological Burden and Influencing Factors from Mycosis Fungoides and Sézary Syndrome Patients in China

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only